B Group, Inc.
DALLAS, TX · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 16, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$162.1M2026 Q3
Positions19
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.80.2%
What Changed This Quarter?
Top Holdings
ADMA
Adma Biologics
20.2%
FTH
Faeth Therapeutics
11.2%
PALI
Palisade Bio
9.5%
NRXP
NRX Pharmaceuticals
7.7%
ZLAB
Zai Lab
7.3%
PRAX
Praxis Precision Medicines
6.0%
SGHT
Sight Sciences
5.6%
TSHA
Taysha Gene Therapies
5.4%
New / Increased
1 new · 3 increased
QTTBNEW
Q32 Bio
0.3%
DRUG
Bright Minds Biosciences
2.9%
+40.7%
GPCR
Structure Therapeutics
3.5%
+28.6%
NRXP
NRX Pharmaceuticals
7.7%
+4.5%
Reduced / Exited
3 reduced · 1 sold out
IOVA
Iovance Biotherapeutics
3.9%
-71.7%
ORKA
Oruka Therapeutics
2.8%
-26.7%
SYRE
Spyre Therapeutics
3.4%
-10.7%
Invesco Qqq TrPUTEXIT
Invesco QQQ Tr
17.3%
Read the 2026-Q2 quarterly report · 13F Filing Calendar
13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.